Hologic Q3 Revenues Bounce 33 Percent; New CEO Conducting Strategic Review | GenomeWeb

NEW YORK (GenomeWeb News) – Hologic reported after the close of the market on Monday that revenues for its fiscal third quarter rose 33 percent year over, helped by the inclusion of revenues from its Gen-Probe acquisition.

The Bedford, Mass.-based firm said that for the three months ended June 29, revenues increased to $626.1 million, up from $470.2 a year ago, but narrowly missed the average Wall Street estimate of $626.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.